Repligen (RGEN) Tops Q1 EPS by 20c; Lowers FY Outlook

Repligen (NASDAQ: RGEN) reported Q1 EPS of $0.92, $0.20 better than the analyst estimate of $0.72. Revenue for the quarter came in at $206.4 million versus the consensus estimate of $185.48 million.

GUIDANCE:

Repligen sees FY2022 EPS of $3.07-$3.15, versus the consensus of $3.25. Repligen sees FY2022 revenue of $770-800 million, versus the consensus of $819.5 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• Designer Brands (DBI) PT Lowered to $6 at UBS
• Kustom Entertainment agrees to buy Tickets For Less operator TFL